出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年7月
羊膜製品市場 : タイプ (凍結保存羊膜、脱水羊膜)、用途 (創傷ケア、眼科、整形外科)、エンドユーザー (病院＆外来手術センター) – 2028年までの世界予測
Amniotic Products Market by Type (Cryopreserved Amniotic Membranes, Dehydrated Amniotic Membranes), Application (Wound Care, Ophthalmology, Orthopedics), End User (Hospital & Ambulatory Surgical Centers) – Global Forecast to 2028
| ページ数 | 175 |
| 図表数 | 139 |
| 種別 | 英文調査報告書 |
| 価格 |
The global Amniotic Products Market is projected to reach USD 1,289 Million by 2028 from USD 900 Million in 2023, at a CAGR of 7.4% during the forecast period. The growth of this market is majorly driven by Increasing number of ophthalmology, cosmetic, and orthopedic surgeries and Strategic Collaborations and Partnerships. However, Challenges associated with cost and affordability may threat the growth of this market.
“Dehydrated Amniotic Membrane in the type of segment to witness the second highest growth during the forecast period.”
Based on the Type, the Amniotic products market is segmented into Cryopreserved Amniotic Membrane, and Dehydrated Amniotic Membrane. The Dehydrated Amniotic Membrane is projected to grow at the second highest CAGR during the forecast period. The significant factors contributing to the growth of this market is its application reliability for instance, Dehydrated amniotic membranes have logistical advantages over cryopreserved amniotic membranes as cryopreserved membranes require specialized storage and transport methods, Dehydrated amniotic membranes can be rehydrated before use, allowing for greater flexibility in their application, Reduced Risk of Disease Transmission as during the dehydration processes, such as freeze-drying, can help inactivate or eliminate potential pathogens present in the amniotic membrane.
“Asia Pacific is estimated to register the third highest CAGR during the forecast period.”
In this report, the amniotic products market is segmented into four major regional segments: North America, Europe, Asia Pacific, Latin America, Middle East & Africa. The market in Asia Pacific is projected to register the third highest growth rate during the forecast period. The growth in this market is primarily driven by the The growing awareness about the benefits of advanced wound care products, the rising geriatric population, increasing prevalence of chronic wounds, and growth in the number of people suffering from pressure ulcers, ophthalmic and orthopedic surgeries.
Breakdown of supply-side primary interviews, by company type, designation, and region:
• By Company Type: Tier 1 (48%), Tier 2 (34%), and Tier 3 (18%)
• By Designation: C-level (33%), Director-level (40%), and Others (27%)
• By Region: North America (36%), Europe (28%), AsiaPacific (19%), Latin America (10%), Middle East & Africa (7%),
List of Companies Profiled in the Report
mimedx (US)
Smith+Nephew (UK)
Organogenesis Inc. (US)
Integra LifeSciences (US)
Stryker (US)
APPLIED BIOLOGICS. (US)
Celularity Inc. (US)
Corza Ophthalmology (US)
Lucina BioSciences (US)
Next Biosciences. (South Africa)
Skye Biologics Holdings, LLC (US)
BioTissue. (US)
Ventris Medical, LLC (US)
Stimlabs LLC (US)
VIVEX Biologics, Inc. (US)
LifeCell (India)
NuVision Biotherapies Ltd (UK)
Genesis Biologics, Inc. (US)
SURGILOGIX (US)
Tides Medical (US)
Orthofix US LLC. (US)
AlloSource (US)
Merakris Therapeutics, Inc. (US)
MTF Biologics (US)
Surgenex (US)
SURGITECH INNOVATION (India)
Research Coverage:
This report studies the amniotic products market based on product and region. The report also analyzes factors (such as drivers, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micromarkets with respect to their growth trends, prospects, and contributions to the total Amniotic Products market. The report forecasts the revenue of the market segments with respect to five major regions.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on Amniotic Products products offered by the top 26 players in the amniotic products market. The report analyzes the amniotic products market by Type, and region.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various securement devices across key geographic regions.
• Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the amniotic products market.
• Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the amniotic products market.
目次
1 INTRODUCTION 22
1.1 STUDY OBJECTIVES 22
1.2 MARKET DEFINITION 22
1.2.1 INCLUSIONS AND EXCLUSIONS 23
1.3 MARKET SCOPE 23
FIGURE 1 AMNIOTIC PRODUCTS MARKET SEGMENTATION 23
1.3.1 REGIONS CONSIDERED 24
1.3.2 YEARS CONSIDERED 24
1.4 CURRENCY CONSIDERED 25
1.5 STAKEHOLDERS 25
1.6 LIMITATIONS 25
1.7 RECESSION IMPACT 26
1.8 SUMMARY OF CHANGES 26
2 RESEARCH METHODOLOGY 27
2.1 RESEARCH DATA 27
FIGURE 2 AMNIOTIC PRODUCTS MARKET: RESEARCH DESIGN 27
2.2 SECONDARY DATA 27
2.2.1 SECONDARY SOURCES 28
2.3 PRIMARY DATA 29
FIGURE 3 PRIMARY SOURCES 30
2.3.1 KEY DATA FROM PRIMARY SOURCES 31
2.3.2 KEY INDUSTRY INSIGHTS 32
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 32
2.4 MARKET SIZE ESTIMATION 33
FIGURE 5 MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH 33
2.4.1 GROWTH FORECAST 34
FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 34
FIGURE 7 TOP-DOWN APPROACH 35
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION 36
FIGURE 8 DATA TRIANGULATION METHODOLOGY 36
2.6 MARKET SHARE ANALYSIS 36
2.7 RESEARCH ASSUMPTIONS 37
2.8 RESEARCH LIMITATIONS 37
2.9 RISK ASSESSMENT 38
2.10 GROWTH RATE ASSUMPTIONS 38
2.11 RECESSION IMPACT ANALYSIS 38
3 EXECUTIVE SUMMARY 39
FIGURE 9 AMNIOTIC PRODUCTS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 39
FIGURE 10 AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 40
FIGURE 11 AMNIOTIC PRODUCTS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 40
FIGURE 12 AMNIOTIC PRODUCTS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION) 41
4 PREMIUM INSIGHTS 42
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN AMNIOTIC PRODUCTS MARKET 42
FIGURE 13 GROWING TARGET PATIENT POPULATION TO DRIVE MARKET 42
4.2 AMNIOTIC PRODUCTS MARKET, BY TYPE 43
FIGURE 14 CRYOPRESERVED AMNIOTIC MEMBRANES SEGMENT TO REGISTER HIGHER CAGR DURING FORECAST PERIOD 43
4.3 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY TYPE AND COUNTRY 43
FIGURE 15 US ACCOUNTED FOR LARGEST MARKET SHARE IN NORTH AMERICA IN 2022 43
4.4 AMNIOTIC PRODUCTS MARKET, BY COUNTRY 44
FIGURE 16 US AND UK TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 44
5 MARKET OVERVIEW 45
5.1 INTRODUCTION 45
FIGURE 17 AMNIOTIC PRODUCTS MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 45
5.2 MARKET DYNAMICS 45
5.2.1 DRIVERS 45
5.2.1.1 Growth in target patient population 45
TABLE 1 GLOBAL PREVALENCE OF DIABETES 46
5.2.1.2 Rising incidence of burn injuries and increasing number of traumatic wounds 47
5.2.1.3 Wound care awareness programs and increasing funding for wound care treatment and management 48
TABLE 2 WOUND CARE AWARENESS INITIATIVES 48
TABLE 3 FUNDING FOR REGENERATIVE MEDICINE RESEARCH BY NIH UNDER 21ST CENTURY CURES ACT 49
TABLE 4 FUNDING INITIATIVES FROM CORPORATE PARTNERSHIPS IN 2022 (USD MILLION) 49
TABLE 5 FUNDING FROM CORPORATE PARTNERSHIPS IN 2021 (USD MILLION) 50
FIGURE 18 ARTICLES RELATED TO AMNIOTIC PRODUCTS PUBLISHED DURING 2010–2021 50
5.2.1.4 Increasing number of amniotic membrane transplantations 51
TABLE 6 NUMBER OF AMNIOTIC MEMBRANE TRANSPLANTATIONS PERFORMED IN UNIVERSITY EYE HOSPITAL TÜBINGEN, GERMANY 51
5.2.1.5 Increasing number of ophthalmology, cosmetic, and orthopedic surgeries 51
5.2.1.6 Strategic collaborations and partnerships 52
5.2.1.7 Favorable reimbursement policies 52
TABLE 7 MEDICARE ALLOWABLE AMOUNTS (USD) 52
5.2.2 OPPORTUNITIES 53
5.2.2.1 Untapped opportunities in emerging economies 53
TABLE 8 STRATEGIC DEVELOPMENTS IN ASIA PACIFIC 54
5.2.2.2 Implementation of 21st Century Cures Act (US) 54
5.2.2.3 Increasing demand for stem cell research and regenerative medicine 54
FIGURE 19 STEM CELL RESEARCH FUNDING FROM 2011 TO 2020 55
TABLE 9 NIH FUNDING FOR CELL-BASED RESEARCH, 2016–2021 (USD MILLION) 55
5.2.3 CHALLENGES 56
5.2.3.1 Complications and limitations associated with use of amniotic membranes 56
5.2.3.2 Ethical and legal concerns of using amniotic membranes 56
5.2.3.3 High cost of amniotic membrane products 57
5.2.3.4 Competition from alternative therapies 57
5.2.4 TRENDS 58
5.2.4.1 Increasing clinical trials for stem cell and chimeric antigen receptor-T cell therapies 58
5.2.4.2 Expanding applications and rising focus on standardization and regulation of amniotic products 58
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 59
5.3.1 REVENUE SHIFT AND REVENUE POCKETS FOR AMNIOTIC PRODUCT MANUFACTURERS 59
5.3.2 REVENUE SHIFT IN AMNIOTIC PRODUCTS MARKET 59
5.4 PRICING ANALYSIS 60
TABLE 10 PRICES OF AMNIOTIC PRODUCTS 60
5.5 SUPPLY CHAIN ANALYSIS 60
FIGURE 20 DIRECT DISTRIBUTION: STRATEGY PREFERRED BY PROMINENT COMPANIES 61
5.6 VALUE CHAIN ANALYSIS 61
FIGURE 21 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING DEVELOPMENT PHASE 61
5.7 ECOSYSTEM ANALYSIS 62
5.7.1 ROLE IN ECOSYSTEM 62
TABLE 11 ROLE OF KEY PLAYERS IN ECOSYSTEM 62
FIGURE 22 KEY PLAYERS IN AMNIOTIC PRODUCTS ECOSYSTEM 63
5.8 TECHNOLOGY ANALYSIS 63
5.9 PATENT ANALYSIS 64
5.10 TRADE ANALYSIS 65
TABLE 12 IMPORT DATA FOR EXTRACTS OF GLANDS OR OTHER ORGANS OR OF THEIR SECRETIONS FOR ORGANO-THERAPEUTIC USE, BY COUNTRY, 2018–2022 (USD THOUSAND) 65
TABLE 13 EXPORT DATA FOR EXTRACTS OF GLANDS OR OTHER ORGANS OR OF THEIR SECRETIONS FOR ORGANO-THERAPEUTIC USE, BY COUNTRY, 2018–2022 (USD THOUSAND) 65
5.11 REGULATORY LANDSCAPE 66
5.11.1 NORTH AMERICA 66
5.11.2 EUROPE 66
5.11.3 EMERGING ECONOMIES 66
5.12 PORTER’S FIVE FORCES ANALYSIS 67
TABLE 14 AMNIOTIC PRODUCTS MARKET: IMPACT OF PORTER’S FIVE FORCES 67
5.12.1 INTENSITY OF COMPETITIVE RIVALRY 67
5.12.2 BARGAINING POWER OF SUPPLIERS 67
5.12.3 BARGAINING POWER OF BUYERS 68
5.12.4 THREAT OF SUBSTITUTES 68
5.12.5 THREAT OF NEW ENTRANTS 68
6 AMNIOTIC PRODUCTS MARKET, BY TYPE 69
6.1 INTRODUCTION 70
6.2 AMNIOTIC MEMBRANES 70
TABLE 15 AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 70
6.2.1 CRYOPRESERVED AMNIOTIC MEMBRANES 70
6.2.1.1 Cryopreserved amniotic membranes to dominate amniotic membranes market during forecast period 70
TABLE 16 CRYOPRESERVED AMNIOTIC MEMBRANES MARKET, BY REGION, 2021–2028 (USD MILLION) 72
6.2.2 DEHYDRATED AMNIOTIC MEMBRANES 72
6.2.2.1 Logistical advantages of dehydrated amniotic membranes over cryopreserved amniotic membranes to drive demand 72
TABLE 17 DEHYDRATED AMNIOTIC MEMBRANES MARKET, BY REGION, 2021–2028 (USD MILLION) 73
7 AMNIOTIC PRODUCTS MARKET, BY APPLICATION 74
7.1 INTRODUCTION 75
7.2 PRIMARY NOTES 75
TABLE 18 AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 75
7.3 WOUND CARE 76
7.3.1 RISING INCIDENCE OF ULCERS, TRAUMATIC AND SURGICAL WOUNDS, AND BURNS TO DRIVE MARKET 76
TABLE 19 AMNIOTIC PRODUCTS MARKET FOR WOUND CARE, BY REGION, 2021–2028 (USD MILLION) 77
7.4 ORTHOPEDICS 77
7.4.1 BENEFITS OFFERED BY AMNIOTIC PRODUCTS FOR ORTHOPEDIC APPLICATIONS TO DRIVE MARKET 77
TABLE 20 AMNIOTIC PRODUCTS MARKET FOR ORTHOPEDICS, BY REGION, 2021–2028 (USD MILLION) 78
7.5 OPHTHALMOLOGY 78
7.5.1 LIGHTWEIGHT, THIN, AND ELASTIC NATURE OF AMNIOTIC MEMBRANES TO DRIVE DEMAND IN OPHTHALMOLOGY 78
TABLE 21 AMNIOTIC PRODUCTS MARKET FOR OPHTHALMOLOGY, BY REGION, 2021–2028 (USD MILLION) 79
7.6 OTHER APPLICATIONS 80
TABLE 22 ESTIMATED NUMBER OF COLORECTAL CANCER CASES AND DEATHS IN US IN 2020, BY AGE 80
TABLE 23 AMNIOTIC PRODUCTS MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 81
8 AMNIOTIC PRODUCTS MARKET, BY END USER 82
8.1 INTRODUCTION 83
TABLE 24 AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 83
8.2 HOSPITALS & AMBULATORY SURGERY CENTERS 83
8.2.1 INCREASING NUMBER OF SURGICAL PROCEDURES TO DRIVE MARKET 83
TABLE 25 AMNIOTIC PRODUCTS MARKET FOR HOSPITALS & ASCS, BY REGION, 2021–2028 (USD MILLION) 85
8.3 OTHER END USERS 85
TABLE 26 AMNIOTIC PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 86
9 AMNIOTIC PRODUCTS MARKET, BY REGION 87
9.1 INTRODUCTION 88
TABLE 27 AMNIOTIC PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 88
9.2 NORTH AMERICA 88
FIGURE 23 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET SNAPSHOT 89
TABLE 28 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 29 NORTH AMERICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 90
TABLE 30 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 90
TABLE 31 NORTH AMERICA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 91
9.2.1 US 91
9.2.1.1 Growing geriatric population and high prevalence of chronic wounds and diabetes to drive market 91
TABLE 32 US: KEY MACRO INDICATORS 92
TABLE 33 US: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 92
TABLE 34 US: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 92
TABLE 35 US: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 93
9.2.2 CANADA 93
9.2.2.1 Rising prevalence of target diseases to drive market 93
TABLE 36 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029 93
TABLE 37 CANADA: KEY MACRO INDICATORS 94
TABLE 38 CANADA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 94
TABLE 39 CANADA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 95
TABLE 40 CANADA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 95
9.2.3 RECESSION IMPACT ON NORTH AMERICA 95
9.3 EUROPE 96
TABLE 41 EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY (% OF GDP) 97
TABLE 42 PREVALENCE OF DIABETES IN EUROPE, 2019 VS. 2045 97
TABLE 43 EUROPE: AMNIOTIC PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 98
TABLE 44 EUROPE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 98
TABLE 45 EUROPE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 98
TABLE 46 EUROPE: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 99
9.3.1 GERMANY 99
9.3.1.1 Increasing incidence of diabetes to drive market 99
TABLE 47 GERMANY: KEY MACRO INDICATORS 100
TABLE 48 GERMANY: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 100
TABLE 49 GERMANY: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 101
TABLE 50 GERMANY: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 101
9.3.2 UK 101
9.3.2.1 High prevalence of diabetes activities to drive market 101
TABLE 51 UK: KEY MACRO INDICATORS 102
TABLE 52 UK: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 102
TABLE 53 UK: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 103
TABLE 54 UK: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 103
9.3.3 FRANCE 103
9.3.3.1 Government support to drive demand for amniotic products 103
TABLE 55 FRANCE: KEY MACRO INDICATORS 104
TABLE 56 FRANCE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 104
TABLE 57 FRANCE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 105
TABLE 58 FRANCE: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 105
9.3.4 REST OF EUROPE 105
TABLE 59 REST OF EUROPE: HEALTHCARE EXPENDITURE, BY COUNTRY, 2010 VS. 2021 (% OF GDP) 107
TABLE 60 REST OF EUROPE: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 107
TABLE 61 REST OF EUROPE: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 107
TABLE 62 REST OF EUROPE: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 108
9.3.5 RECESSION IMPACT ON EUROPE 108
9.4 ASIA PACIFIC 108
FIGURE 24 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET SNAPSHOT 109
TABLE 63 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 64 ASIA PACIFIC: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 65 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110
TABLE 66 ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 111
9.4.1 CHINA 111
9.4.1.1 Increasing incidence of diabetes and growth in geriatric population to drive market 111
TABLE 67 CHINA: KEY MACRO INDICATORS 112
TABLE 68 CHINA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 69 CHINA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 112
TABLE 70 CHINA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 113
9.4.2 JAPAN 113
9.4.2.1 Growing geriatric population to drive market 113
TABLE 71 JAPAN: KEY MACRO INDICATORS 114
TABLE 72 JAPAN: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 114
TABLE 73 JAPAN: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 114
TABLE 74 JAPAN: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 115
9.4.3 REST OF ASIA PACIFIC 115
TABLE 75 REST OF ASIA PACIFIC: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021 116
TABLE 76 REST OF ASIA PACIFIC: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 116
TABLE 77 REST OF ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 117
TABLE 78 REST OF ASIA PACIFIC: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 117
9.4.4 RECESSION IMPACT ON ASIA PACIFIC 117
9.5 LATIN AMERICA 118
9.5.1 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET 118
TABLE 79 LATIN AMERICA: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021 118
TABLE 80 LATIN AMERICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 81 LATIN AMERICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 119
TABLE 82 LATIN AMERICA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 119
9.6 MIDDLE EAST & AFRICA 120
9.6.1 GROWTH IN HEALTHCARE INFRASTRUCTURE AND GOVERNMENT INITIATIVES TO DRIVE MARKET 120
TABLE 83 MIDDLE EAST & AFRICA: DIABETES PREVALENCE (% OF POPULATION AGED 20–79), BY COUNTRY, 2021 121
TABLE 84 MIDDLE EAST & AFRICA: AMNIOTIC MEMBRANES MARKET, BY TYPE, 2021–2028 (USD MILLION) 121
TABLE 85 MIDDLE EAST & AFRICA: AMNIOTIC PRODUCTS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 122
TABLE 86 MIDDLE EAST & AFRICA: AMNIOTIC PRODUCTS MARKET, BY END USER, 2021–2028 (USD MILLION) 122
10 COMPETITIVE LANDSCAPE 123
10.1 OVERVIEW 123
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 123
TABLE 87 OVERVIEW OF STRATEGIES ADOPTED BY KEY AMNIOTIC PRODUCT MARKET PLAYERS 123
10.3 MARKET SHARE ANALYSIS, 2022 124
TABLE 88 AMNIOTIC PRODUCTS MARKET: DEGREE OF COMPETITION (2022) 124
10.4 REVENUE SHARE ANALYSIS, 2022 125
FIGURE 25 AMNIOTIC PRODUCTS MARKET: REVENUE ANALYSIS OF TOP FOUR MARKET PLAYERS, 2020–2022 126
10.5 COMPANY EVALUATION QUADRANT 126
10.5.1 STARS 126
10.5.2 EMERGING LEADERS 126
10.5.3 PERVASIVE PLAYERS 126
10.5.4 PARTICIPANTS 127
FIGURE 26 AMNIOTIC PRODUCTS MARKET: COMPANY EVALUATION MATRIX, 2022 127
10.6 SMALL AND MEDIUM-SIZED ENTERPRISE/STARTUP EVALUATION QUADRANT 128
10.6.1 PROGRESSIVE COMPANIES 128
10.6.2 STARTING BLOCKS 128
10.6.3 RESPONSIVE COMPANIES 128
10.6.4 DYNAMIC COMPANIES 128
FIGURE 27 AMNIOTIC PRODUCTS MARKET: SMALL AND MEDIUM-SIZED ENTERPRISE/ STARTUP EVALUATION MATRIX, 2022 129
10.7 COMPETITIVE BENCHMARKING 129
TABLE 89 AMNIOTIC PRODUCTS MARKET: DETAILED LIST OF KEY SMALL AND MEDIUM-SIZED ENTERPRISES/STARTUPS 129
10.8 COMPETITIVE SCENARIO 130
10.8.1 PRODUCT LAUNCHES 130
TABLE 90 PRODUCT LAUNCHES 130
10.8.2 DEALS 130
TABLE 91 DEALS 130
10.8.3 OTHERS 131
TABLE 92 OTHERS 131
10.9 COMPANY FOOTPRINT ANALYSIS 132
TABLE 93 COMPANY FOOTPRINT ANALYSIS 132
TABLE 94 COMPANY PRODUCT FOOTPRINT 133
TABLE 95 COMPANY REGIONAL FOOTPRINT 134
11 COMPANY PROFILES 135
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
11.1 KEY PLAYERS 135
11.1.1 MIMEDX GROUP, INC. 135
TABLE 96 MIMEDX GROUP, INC.: COMPANY OVERVIEW 135
FIGURE 28 MIMEDX GROUP, INC.: COMPANY SNAPSHOT (2022) 136
11.1.2 SMITH+NEPHEW 139
TABLE 97 SMITH+NEPHEW: COMPANY OVERVIEW 139
FIGURE 29 SMITH+NEPHEW: COMPANY SNAPSHOT (2022) 140
11.1.3 ORGANOGENESIS INC. 142
TABLE 98 ORGANOGENESIS INC.: COMPANY OVERVIEW 142
FIGURE 30 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2022) 142
11.1.4 INTEGRA LIFESCIENCES 145
TABLE 99 INTEGRA LIFESCIENCES: COMPANY OVERVIEW 145
FIGURE 31 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2022) 146
11.1.5 STRYKER 149
TABLE 100 STRYKER: COMPANY OVERVIEW 149
FIGURE 32 STRYKER: COMPANY SNAPSHOT (2022) 150
11.1.6 APPLIED BIOLOGICS 152
TABLE 101 APPLIED BIOLOGICS: COMPANY OVERVIEW 152
11.1.7 CELULARITY INC. 153
TABLE 102 CELULARITY INC.: COMPANY OVERVIEW 153
11.1.8 CORZA OPHTHALMOLOGY 154
TABLE 103 CORZA OPHTHALMOLOGY: COMPANY OVERVIEW 154
11.1.9 LUCINA BIOSCIENCES 155
TABLE 104 LUCINA BIOSCIENCES: COMPANY OVERVIEW 155
11.1.10 NEXT BIOSCIENCES 156
TABLE 105 NEXT BIOSCIENCES: COMPANY OVERVIEW 156
11.1.11 SKYE BIOLOGICS HOLDINGS, LLC 157
TABLE 106 SKYE BIOLOGICS HOLDINGS, LLC: COMPANY OVERVIEW 157
11.1.12 SURGENEX 158
TABLE 107 SURGENEX: COMPANY OVERVIEW 158
11.2 OTHER PLAYERS 159
11.2.1 BIOTISSUE 159
11.2.2 VENTRIS MEDICAL, LLC 160
11.2.3 STIMLABS LLC 161
11.2.4 VIVEX BIOLOGICS, INC. 162
11.2.5 LIFECELL 163
11.2.6 NUVISION BIOTHERAPIES LTD 164
11.2.7 GENESIS BIOLOGICS, INC. 165
11.2.8 SURGILOGIX 166
11.2.9 TIDES MEDICAL 167
11.2.10 ORTHOFIX US LLC 168
11.2.11 ALLOSOURCE 169
11.2.12 MERAKRIS THERAPEUTICS, INC. 170
11.2.13 MTF BIOLOGICS 171
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
12 APPENDIX 172
12.1 DISCUSSION GUIDE 172
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 176
12.3 CUSTOMIZATION OPTIONS 178
12.4 RELATED REPORTS 178
12.5 AUTHOR DETAILS 179